Child sexual abuse (CSA) evaluations frequently yield normal or nonspecific anogenital findings, even in cases later substantiated through investigation. This reality is often misunderstood in clinical, legal, and multidisciplinary contexts, where the absence of physical injury may be incorrectly interpreted as the absence of abuse. The purpose of this narrative review is to explain why most CSA examinations are normal and to provide an evidence-based framework for interpreting and communicating these findings in a manner that is medically accurate and forensically defensible. A targeted review of contemporary guidelines, large clinical series, healing studies, forensic evidence collection literature, and sexually transmitted infection (STI) testing recommendations was conducted. Evidence consistently demonstrates that low physical yield is driven by several converging factors: the nature of abusive acts, the elasticity and rapid healing capacity of pediatric anogenital tissues, delayed disclosure leading to non-acute examinations, variability in examiner experience and documentation quality, and the time-sensitive nature of biological evidence recovery. STI findings are uncommon overall and require contextual interpretation, including consideration of testing methods and potential nonsexual transmission pathways. Importantly, a normal examination neither confirms nor excludes CSA. Misinterpretation commonly arises from imprecise terminology, binary reasoning, and overreliance on physical findings as proof. This review emphasizes the need for standardized, evidence-based communication in medical reports and testimony to prevent medico-legal misunderstanding. Practical language guidance is provided to assist clinicians in accurately conveying the limitations and significance of normal findings. Understanding that "normal is common" in CSA evaluations is essential to reducing harm, supporting trauma-informed care, and strengthening the integrity of multidisciplinary decision-making.
child sexual abuseanogenital examinationnormal findingssexually transmitted infections
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.
HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
Advanced Health Science and Technology Journal · مجلد 2 (1) · 21-26
Abstract Aspirin is one of the oldest and most used anti-platelet medications for the prevention of cardiovascular diseases. There has been conflicting research recently about how body weight affects the antiplatelet effectiveness of aspirin. The purpose of this narrative review was to examine the recent research on the connection between aspirin responsiveness, platelet function, and obesity. To find patterns and discrepancies, pertinent research from PubMed, Scopus, and Google Scholar was rigorously examined and compiled. While some studies showed no discernible effect, others highlighted methodological and population-specific variations by reporting decreased aspirin efficacy in people with higher body weight because of increased platelet reactivity, aspirin deactivation, and altered pharmacokinetics, underscoring the need for well-designed, large-scale clinical investigations. The need for carefully planned, extensive clinical studies is highlighted by the fact that the evidence is still equivocal overall. A better understanding of these mechanisms may support the development of personalized antiplatelet strategies, including tailored aspirin dosing in selected subgroups such as obese patients with high thrombotic risk.
Background: Relapsing-remitting multiple sclerosis is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies may provide stronger inflammatory control and improve long-term outcomes. Objective: This systematic review and meta-analysis aimed to compare early initiation of high-efficacy disease-modifying therapies with escalation or delayed treatment strategies in adults with relapsing-remitting multiple sclerosis. Methods: PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with relapsing-remitting multiple sclerosis treated with either early high-efficacy disease-modifying therapies or escalation/delayed strategies. Outcomes included annualized relapse rate, Expanded Disability Status Scale change, and delta-Expanded Disability Status Scale. Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models. Results: Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with lower annualized relapse rate than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted delta-EDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation. Conclusion: Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.
The rising demand for skin-lightening products has brought glutathione, a tripeptide with antioxidant properties and melanogenesis-regulating effects, into focus as a potentially safer alternative to conventional agents. This narrative review aims to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. Oral administration shows significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability. Intravenous glutathione, although having rapid action, is associated with serious safety concerns like anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. Until such data are available, clinicians and consumers should exercise caution to ensure safe and effective dermatological practices, particularly with intravenous use.
AIM: To evaluate the efficacy and outcomes of integrative technologies employed in nursing-led interventions for the management of diabetes. BACKGROUND: With the global rise in diabetes prevalence, there is growing interest in digital health solutions to improve disease self-management. Nurses are increasingly leveraging technologies, such as mobile applications, wearable devices, and telehealth platforms, to support individuals with diabetes. However, the effectiveness and implementation outcomes of such nursing-led digital interventions remain variably reported in the literature. METHODS: A systematic review was conducted following PRISMA 2020 guidelines. Comprehensive five database searches (PubMed, CINAHL, Scopus, Web of Science, and Embase) identified randomized controlled trials (RCTs) from 2013 to 2024. Studies were included if they involved nurse-led interventions incorporating digital technologies for diabetes management. Data were synthesized using narrative and thematic analysis. Risk of bias was assessed using the RoB 2 tool. RESULTS: Thirteen RCTs involving diverse technologies demonstrated improvements in glycemic control (HbA1c reduction), self-management behaviors, and quality of life. Interventions incorporating personalized coaching, regular follow-up, and patient-centered feedback were particularly effective. Most studies were rated as low risk of bias, though some showed concerns regarding reporting practices and intervention fidelity. CONCLUSION: Nursing-led digital health interventions can significantly enhance diabetes care outcomes. Their success is contingent upon sustained patient engagement, nurse training, and organizational support. Broader implementation requires addressing digital literacy and system-level integration challenges. IMPLICATIONS FOR PRACTICE: Nurse-led technologies should be embedded in care models to support scalable, personalized, and effective diabetes self-management across diverse settings. CLINICAL TRIAL NUMBER: Not applicable.
diabetes managementnurse-led interventiondigital health technologiesmobile health apps
BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common urological disorder in older males, often treated with prostate artery embolization (PAE) to alleviate lower urinary tract symptoms. While traditional embolic materials like microspheres are common, issues such as symptom recurrence and non-target embolization remain. This systematic review evaluates the safety and effectiveness of n-butyl cyanoacrylate (NBCA) glue as an alternative embolic agent for PAE. MATERIALS AND METHODS: A thorough search was performed across databases including PubMed, ScienceDirect, Cochrane, Google Scholar, Scopus, and MEDLINE. Studies were included if they assessed NBCA glue for PAE in BPH patients. Exclusions were made for reviews, non-English articles, conference abstracts, and studies not using glue or ethiodized oil mixtures. The Methodological Index for Non-Randomized Studies criteria was used to assess bias risk, and due to varied outcome measures, a narrative synthesis was conducted. RESULTS: Six studies involving 667 patients met the inclusion criteria. The age in mean ± SD across studies ranged from 67.5 ± 7.8 to 72.6 ± 10.5 with most patients presenting with moderate to severe BPH unresponsive to medication. NBCA glue-based procedures showed high technical success rates and shorter procedure times. International Prostate Symptom Score improvement was reported in 83-94% of patients across all studies with associated quality of life significantly enhanced in up to 94% of patients as well. Prostate volume reduction ranged from 11% to 40.5%, depending on follow-up duration. PSA levels and medication use decreased, and erectile function was mostly preserved, though results varied. Minor complications like groin hematomas and post-embolization syndrome occurred in 4-22% of patients, with no major adverse events reported. CONCLUSION: This review assesses NBCA-based glue as a potential embolic agent in PAE for BPH. The evidence suggests promising short-term outcomes with a favorable safety profile, though findings remain preliminary due to small sample sizes and short follow-up. Larger multicenter randomized trials are therefore needed to validate these results and guide clinical practice.
Gut microbiome-targeted therapies have shown promise in promoting the outcomes of metabolic inflammation-related disease management. This review aims to assess the effectiveness of microbiome-targeted interventions and pinpoint the most promising therapies for clinical implementation. Following the PRISMA 2020 standards, we searched four main databases: PubMed, EMBASE, Scopus, and the Cochrane Library. We integrated medical subject headings (MeSH) and free-text keywords search pertinent to gut microbiome-targeted interventions, along with related outcomes such as inflammation and insulin resistance. English studies were conducted on primary adults with a metabolic disease diagnosis or deemed a high risk, and were mandated to report at least one outcome pertinent to metabolic health or systemic inflammation. To assess the risk bias, data were extracted, and the Cochrane Risk of Bias (RoB) 2.0 tool was employed. Fifteen studies fulfilled the inclusion criteria. A narrative synthesis was conducted. We found that probiotics significantly enhanced insulin resistance (HOMA-IR), reduced circulating endotoxin levels, decreased visceral fat, BMI, and fat mass, and increased beneficial taxa with obesity-associated bacteria reduction. However, inconsistent outcomes were shown for lipid parameters. Prebiotic therapies showed significant decreases in fasting glucose in overweight people, and insulin levels and HOMA-IR in patients with metabolic syndrome, enhanced anti-inflammatory effects (31% C-reactive protein (CRP) reduction, decreased interleukin (IL)-6, tumor necrosis factor-alpha (TNF)-α, and lipopolysaccharide (LPS) levels), and promoted butyrate-producing bacteria. Synbiotic interventions showed complementary benefits for glucose metabolism and body composition. Fecal microbiota transplantation (FMT) studies indicated improved insulin sensitivity and donor microbiota engraftment in responders. Fiber-rich diet trials markedly improved HbA1c levels in diabetic and prediabetic individuals. In conclusion, prebiotics demonstrated the most consistent metabolic and anti-inflammatory benefits across multiple parameters. Probiotics showed targeted effects on insulin resistance and body composition but inconsistent lipid outcomes. FMT and synbiotics require further investigation to establish clinical efficacy. This evidence supports prebiotics as a priority intervention for metabolic disease management through microbiome modulation.
Plastic and reconstructive surgery increasingly depends on data-driven instruments to improve clinical decision-making. Machine learning (ML), through its capacity to analyze intricate, high-dimensional data, presents novel prospects for forecasting surgical outcomes with enhanced accuracy compared to traditional statistical models. This systematic study evaluates the extent, efficacy, and methodological rigor of ML applications in plastic and reconstructive surgery, encompassing burn treatment, microsurgical reconstruction, and breast surgery. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 standards, we searched four main databases for research published between January 2015 and March 2025. Eligible papers used ML models to predict clinical outcomes in plastic or reconstructive surgery and provided quantifiable performance indicators. Data were retrieved using the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) and Prediction Model Risk of Bias Assessment Tool (PROBAST) frameworks, then synthesized narratively. We included eleven studies that had more than 34,000 patients. Random forests, neural networks, and gradient boosting have emerged as the most prevalent and highest-performing models, with several attaining AUCs exceeding 0.90. Notwithstanding encouraging outcomes, the majority of research depended on internal validation, with only one performing external validation. Calibration reporting and data transparency were constrained. The majority of studies exhibited a high or moderate risk of bias. In summary, ML models provide significant prediction accuracy in plastic surgery; yet, they are limited by methodological deficiencies that impede clinical implementation. Future initiatives must prioritize external validation, repeatability, and ethical execution to facilitate the safe and successful incorporation into surgical practice.
Objective This study evaluated the impact of adenotonsillectomy on asthma symptoms in children by combining observational evidence with pooled analysis.Data sources We searched MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, Web of Science, ProQuest, and Scopus from inception to March 17, 2025.Study selection Eligible studies assessed asthma outcomes in children undergoing adenotonsillectomy using retrospective or prospective cohort designs, case series, or database analyses. Eleven studies involving 74,204 participants were identified. Outcomes included asthma control scores (ACT/cACT), acute asthma exacerbations (AAEs), emergency department (ED) visits, oral corticosteroid use, hospitalization, inflammatory biomarkers, and atopic risk. Risk of bias was evaluated using ROBINS-I.Results Meta-analysis incorporated five studies with 52,479 participants. Adenotonsillectomy improved ACT/cACT scores by a mean of 2.5 points (95% CI:1.6–3.4; I2=0%), indicating better asthma control. A reduced risk of AAEs was observed (RD = 0.29; 95% CI:0.01–0.58), though with extreme heterogeneity (I2=100%). ED visits showed a small but significant reduction (MD=–0.01; 95% CI:0.00–0.02; I2=0%). Narrative synthesis found corticosteroid courses decreased by 23.7%, hospitalization rates fell by up to 35.8%, and patients reported improved quality of life and lower inflammatory biomarkers. However, most studies carried moderate to severe risk of bias due to confounding and selection issues.Conclusions Adenotonsillectomy may improve asthma control, reduce ED visits, and lessen medication use and hospitalization among children. Evidence regarding its effect on exacerbations remains inconsistent, and causality cannot be inferred due to reliance on observational data. Well-designed prospective controlled trials are needed to confirm effectiveness and clarify underlying mechanisms.
Annals of Medicine and Surgery · مجلد 88 (3) · 2298-2311
Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease (PAD), driven by both advanced atherosclerosis and chronic inflammation. Despite advancements in revascularization and medical therapy, outcomes remain poor. Inflammation has emerged as a key therapeutic target, and several anti-inflammatory agents are under investigation for potential benefit in CLTI. A comprehensive literature review was conducted using PubMed, Scopus, Embase, Google Scholar, and Web of Science to identify studies published between 1990 and 2025. Keywords included "chronic limb-threatening ischemia," "peripheral artery disease," "colchicine," "canakinumab," "methotrexate," "NLRP3 inflammasome," and "anti-inflammatory therapy." Eligible studies included original research, clinical trials, systematic reviews, and relevant guidelines focused on inflammation-targeted interventions in atherosclerosis and limb ischemia. Colchicine has shown significant reductions in major adverse cardiovascular events in large trials and retrospective PAD studies, though no randomized controlled trials (RCTs) have specifically addressed CLTI. Canakinumab reduced inflammatory biomarkers and improved walking performance in PAD but had no effect on plaque progression. Methotrexate did not demonstrate cardiovascular benefit in the Cardiovascular Inflammation Reduction Trial. Preclinical agents targeting the NLRP3 inflammasome (e.g., MCC950) have shown anti-inflammatory effects but lack human data. Nutraceuticals, including omega-3 fatty acids and polyphenols, may offer adjunctive benefits, though evidence remains limited. Inflammation-modulating therapies hold promise as adjuncts in CLTI management, potentially improving outcomes by targeting the underlying immune mechanisms of disease progression. However, current evidence is insufficient for clinical adoption in CLTI. Large-scale, well-designed RCTs focusing on limb-specific outcomes are necessary to clarify the role of these therapies in high-risk vascular populations.
Advances in computational intelligence and robotics book series · 1-26
This chapter explores the profound impact of artificial intelligence (AI) on pharmaceutical research, particularly focusing on its integration into drug discovery, development, and clinical trial processes. The narrative details how AI-driven methodologies like predictive modeling, virtual screening, and machine learning revolutionize the identification and validation of drug targets and compounds. Additionally, the chapter discusses the application of AI in optimizing clinical trial designs, enhancing patient recruitment, and monitoring trial data in real-time. Ethical considerations including data privacy, bias, and the need for transparency in AI applications are critically analyzed to underscore the necessity for ethical guidelines and regulatory compliance in the evolving landscape of AI-driven pharmaceutical research. The comprehensive overview provided by the authors demonstrates how AI technologies not only accelerate drug development processes but also improve their efficacy, safety, and cost-efficiency.
drug discoverydrug developmentclinical trial designvirtual screening